ArticleEchocardiography (Mount Kisco, N.Y.)2026
Echocardiographic Markers of Cardiac Response to Therapy in Patients with Light Chain Amyloidosis.
Article in Echocardiography (Mount Kisco, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Monitoring of Treatment Response in Light-chain Cardiac Amyloidosis-Does Echocardiography Have a Role?Echocardiography (Mount Kisco, N.Y.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to identify echocardiographic parameters which correlate with cardiac response to treatment in patients with light chain cardiac amyloidosis (AL-CA).
methodsWe identified 39 patients with AL-CA treated at City of Hope and divided them into two cohorts; cardiac responders as defined by improvement in global longitudinal strain (GLS) over time and cardiac non-responders as defined by no change or worsening in GLS. We then compared baseline demographics and echocardiographic parameters between the two groups.
resultsThere were 16 cardiac responders and 23 cardiac non-responders identified. Correlation between changes in GLS was compared with change in other echocardiographic parameters. The change in GLS correlated with changes in left ventricular ejection fraction (LVEF) (r = -0.44, p < 0.01), stroke volume index (r = -0.05, p < 0.01), posterior wall thickness (r = 0.41, p = 0.01), right ventricular (RV) free wall strain (r = 0.66, p < 0.01), right ventricular four-chamber longitudinal strain (r = 0.67, p < 0.01), left atrial conduit strain (r = 0.46, p < 0.01), left atrial reservoir strain (r = -0.63, p < 0.01), and left atrial contractile strain (r = 0.48, p < 0.01). At less than 1 year, there was a positive correlation between change in GLS and change in RV free wall strain (r = 0.73, p < 0.01) and change in right ventricular four-chamber longitudinal strain (r = 0.75, p < 0.01).
conclusionImprovement in GLS correlated with improvement in RV and left atrial strain measurements in AL-CA patients receiving treatment. Changes in RV strain were seen early, within 1 year of treatment. Our study suggests that strain imaging in conjunction with cardiac biomarkers can provide a comprehensive assessment of cardiac response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.